Synopsis
The majority of drugs acting by novel mechanisms are identified in phenotypic
screening assays. However, the subsequent identification of the relevant targets is
frequently a challenging and tedious exercise. Recent advances in the field have
shown promise for the more efficient execution of target identification and this
symposium brings together experienced scientists in this field. If you are working
on or interested in phenotypic screening, this symposium will allow you to exchange
ideas and experiences, and to understand the critical issues. It will be attended by
scientists from academia and different industries (pharma, crop sciences) and
promises to be a highly stimulating meeting.
The meeting is being organised jointly by the BMCS of the Royal Society of
91AV and the DMCCB of the Swiss Chemical Society, together with
representatives from Syngenta and Roche on the organising committee.
For more information see http://www.maggichurchouseevents.co.uk/bmcs/
or http://www.rsc.org/bmcs
The majority of drugs acting by novel mechanisms are identified in phenotypic
screening assays. However, the subsequent identification of the relevant targets is
frequently a challenging and tedious exercise. Recent advances in the field have
shown promise for the more efficient execution of target identification and this
symposium brings together experienced scientists in this field. If you are working
on or interested in phenotypic screening, this symposium will allow you to exchange
ideas and experiences, and to understand the critical issues. It will be attended by
scientists from academia and different industries (pharma, crop sciences) and
promises to be a highly stimulating meeting.
The meeting is being organised jointly by the BMCS of the Royal Society of
91AV and the DMCCB of the Swiss Chemical Society, together with
representatives from Syngenta and Roche on the organising committee.
For more information see http://www.maggichurchouseevents.co.uk/bmcs/
or http://www.rsc.org/bmcs
